House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Dermatology

Psoriasis: topical therapy and severity assessment

AAD / NPF · 2021 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The joint AAD–NPF guidance covers topical treatment of psoriasis, clinical severity assessment and the evidence for complementary approaches. These official highlights support practical treatment selection but do not reproduce the complete prescribing recommendations.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Choosing and combining topical treatment

  • Topical corticosteroids are recommended for plaque psoriasis outside intertriginous areas. Treatment beyond 12 weeks may be considered with careful physician supervision. [1]
  • Vitamin D analogues, tazarotene and calcineurin inhibitors can be used alone or with corticosteroids as steroid-sparing options. Alternating steroid and steroid-sparing treatment has an important role in chronic management. [1]
  • Emollients, salicylic acid, anthralin and coal tar are additional topical options, either alone or combined with topical corticosteroids. [1]
  • Topical treatments may accompany biologic or other systemic therapies to improve treatment efficacy. [1]

Assess severity and patient impact

  • Body surface area (BSA), physician global assessment (PGA) and BSA × PGA can be used in routine practice. PASI is recommended for clinical trials rather than routine clinical practice. [1]
  • Symptom and quality-of-life tools such as DLQI, PSI and pruritus assessment can provide useful information about the patient’s quality of life. [1]

Interpret complementary-treatment evidence cautiously

  • The guideline does not recommend for or against the assessed complementary approaches because evidence is insufficient or conflicting. The review covers traditional Chinese medicine, specified herbal products, dietary interventions and supplements, and mind–body interventions; listing them is not an endorsement. [1]

Limitations and use

  • Only the official topical-therapy and severity-assessment highlights are covered. The source does not establish specific drug strengths, application schedules or all site-specific prescribing precautions. Other psoriasis guideline sections are outside this summary.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Psoriasis: topical therapy and severity assessment — focused recommendation source

    Selected recommendation material consulted

Clinical practice guideline

Publication details

Issuing organisation
AAD / NPF
First published
30 July 2020
Resource type
Clinical practice guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Choosing and combining topical treatment
  • Assess severity and patient impact
  • Interpret complementary-treatment evidence cautiously
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House